The Src homology 2 phosphotyrosyl phosphatase (SHP2) is a nonreceptor-type phosphatase that acts as a positive transducer of receptor Tyr kinase (RTK) signaling, particularly the Ras-REK and PI3K-Akt pathways. Recently, we have demonstrated that SHP2 is required for cell transformation induced by the constitutively active fibroblast growth factor receptor 3 (K/E-FR3) (Oncogene, 22,(6909)(6910)(6911)(6912)(6913)(6914)(6915)(6916)(6917)(6918). In that study, we had detected a phosphotyrosyl protein of B100 KDa (p100) in cells expressing dominant-negative SHP2 (R/E-SHP2), but its identity and relevance in SHP2-meditaed transformation was not known. Here, we report the identification of p100 as a-catenin, a vinculin-related protein involved in adherens junction-mediated intercellular adhesion. We show that a-catenin becomes Tyr phosphorylated in intercellular adhesion-dependent manner and this event is counteracted by SHP2. Substrate trapping in intact cells and immunocomplex phosphatse assays confirmed that a-catenin is in deed an SHP2 substrate. Tyr phosphorylation of a-catenin enhances its translocation to the plasma membrane and its interaction with bcatenin, leading to enhanced actin polymerization and stabilization of adherens junction-mediated intercellular adhesion, a phenomenon commensurate with loss of the transformation phenotype. Site-directed mutagenesis studies also suggested that Tyr phosphorylation of a-catenin enhances its inhibitory role on cell transformation. Based on our previous work and the current report, we demonstrate that mediation of cell transformation by SHP2 is a complex process that involves modulation of the Ras-ERK and PI3K-Akt signaling pathways, intercellular adhesion, focal adhesion and actin cytoskeletal reorganization. To our knowledge, this is the first report showing regulation of a-catenin function by Tyr phosphorylation and its inhibitory effect on cell transformation.
Introduction
Receptor tyrosine kinase (RTK)-induced signal transduction is regulated by a family of enzymes called phosphotyrosyl phosphatases (PTPs) (Tonks and Neel, 2001) . PTPs are classified as transmembrane or nontransmembrane depending on their location within a cell or as classical or dual-specificity PTP depending on their substrate specificity (Tonks and Neel, 2001; Alonso et al., 2004) . The Src homology 2 PTP (SHP2) is a nontransmembrane classical PTP, which primarily plays a positive role in RTK signaling in vertebrates Feng and Pawson, 1994; Frearson and Alexander, 1998; Hadari et al., 1998; Agazie and Hayman, 2003b) . Also, Corkscrew, the Drosophila melanogaster counterpart of SHP2, is a positive effector of the Torso RTK signaling (Cleghon et al., 1998) . On the other hand, the close relative SHP1 and the highly studied PTP1B are negative regulators of RTK signaling (Feng and Pawson, 1994; D'Ambrosio et al., 1995; Krautwald et al., 1996; Salmeen et al., 2000; Tonks, 2003) . SHP2 directly interacts with autophosphorylated RTKs or indirectly via adaptor proteins (Kuhne et al., 1993; Lechleider et al., 1993; Tomic et al., 1995; Hadari et al., 1998; Cunnick et al., 2000; Schaeper et al., 2000) . Most RTK signaling is dependent on SHP2 as a downstream effector. However, the molecular mechanism of SHP2 in RTK signaling has been very difficult to uncover. Recently, a mechanism for the role of SHP2 in EGFR-induced activation of the Ras-ERK (ERK for extracellular signal regulated kinase) signaling pathway was described (Agazie and Hayman, 2003a) . SHP2 increases the half-life of activated Ras (GTP-Ras) by obstructing the process of Ras inactivation catalysed by Ras GTPase activating protein (RasGAP).
SHP2 possesses two tandemly arranged SH2 domains in the N-terminal region, and a PTP domain in the C-terminal region Feng and Pawson, 1994) and both of these domains are essential for its biological activity Feng and Pawson, 1994; Tang et al., 1995; Bennett et al., 1996; Saxton et al., 1997 Saxton et al., , 2000 . It also possesses two tyrosine phosphorylation sites and a proline-rich-motif (-PXXP-) in the extreme C-terminal region, but the function significance of this region has not been established (Deb et al., 1998 ; O'Reilly and Neel, 1998; Araki et al., 2003) .
The crystal structure of SHP2 show that the protein assumes a 'closed conformation' when inactive and an 'open conformation' when active (Hof et al., 1998; Neel et al., 2003) . The closed conformation is achieved by the interaction of the PTP and N-SH2 domains physically impeding the PTP domain from binding to target substrates. Engagement of the N-SH2 domain with phosphotyrosine (Tyr(P)) relieves the PTP domain and renders the enzyme active (Hof et al., 1998) . This is supported by the findings that mutation of Asp61 and Glu76 of the N-SH2 to Ala, residues that mediate the interaction with the PTP domain, produces a constitutively active SHP2 (O'Reilly et al., 2000) .
Recent findings show that SHP2 is an important player in various disease conditions. First, gain-offunction SHP2 mutations (O'Reilly et al., 2000) were discovered in Noonan syndrome-associated leukemias (Tartaglia et al., 2003; Bentires-Alj et al., 2004; Mohi et al., 2005) . And second, overexpression of SHP2 in vascular smooth muscle cells has been correlated with enhanced development of atherosclerosis (Seki et al., 2002) . Experimentally, SHP2 has been shown to be required for cell transformation induced by v-Src (Hakak et al., 2000) . More recently, we have demonstrated that SHP2 is essential for cell transformation induced by the constitutively active FGFR3 (K650E-FGFR3), hereinafter referred to as K/E-FR3 (Agazie et al., 2003) . Expression of dominant-negative SHP2 (R465E-SHP2), hereinafter referred to as R/E-SHP2, reverses cell transformation as evidenced by morphological changes, inability to form foci in culture and reduced growth rate. Further biochemical analysis showed that reduction in cell growth and reversion of the transformed phenotype correlates with inhibition of the Ras-ERK and the PI3K-Akt signaling pathways (Agazie et al., 2003) . In that study, we had detected a phosphotyrosyl protein of B100 KDa (p100) that coprecipitated with K/E-FR3 in cells expressing R/E-SHP2, but the identity of this protein as well as its relevance in SHP2-meditaed and K/E-FR3-induced cell transformation was not known. Here, we report the identification of p100 as a-catenin by a combination of substrate trapping, mass spectroscopy and immunoblot analysis. a-Catenin is a vinculin-related protein that plays a structural and regulatory role in adherens junction-mediated intercellular adhesion, but its regulation by Tyr phosphorylation or its importance in cell transformation was not known. We show that a-catenin becomes Tyr phosphorylated in intercellular adhesiondependent manner, and this event is counteracted by SHP2. We further show that Tyr phosphorylation of a-catenin enhances its translocation to the plasma membrane and its interaction with b-catenin, leading to enhanced actin polymerization, crosshatching of actin filaments and stabilization of adherens junction-mediated intercellular adhesion, a phenomenon commensurate with loss of the transformation phenotype. Thus, modulation of the Tyr phosphorylation of a-catenin by SHP2 positively modulates cell transformation.
Results
We have recently demonstrated that SHP2 mediates the transformation of NIH-3T3 cells by K/E-FR3 via positively modulating the Ras-ERK and PI3K-Akt signaling pathways (Agazie et al, 2003) . We have further shown that a phosphotyrosyl protein of B100 KDa (p100) coprecipitates with K/E-FR3 in cells expressing R/E-SHP2 suggesting that this protein could be a potential SHP2 substrate (Agazie et al., 2003) . However, the identity of this protein as well as its relevance in SHP2-meditaed and K/E-FR3-induced cell transformation was not investigated. Therefore, we set out to identity and characterize p100 as an SHP2 substrate and to determine how modulation of the Tyr phosphorylation p100 by SHP2 contributes to cell transformation by K/E-FR3.
Isolation and identification of p100 in K/E-FR3C NIH-3T3 cells transformed with K/E-FR3, referred to as K/E-FR3C, were previously described (Agazie et al., 2003) . For isolation of p100, we first produced K/E-FR3C expressing vector control, wild-type SHP2 (WT-SHP2) or dominant-negative SHP2 (R/E-SHP2) by infecting with recombinant retroviruses as described previously (Agazie et al., 2003; Agazie and Hayman, 2003b) . As shown in Figure 1a , ectopic expression of WT-SHP2 did not cause any change, but that of R/E-SHP2 reversed K/E-FR3-induced transformation. Furthermore, WT-SHP2 enhanced, while R/E-SHP2 inhibited the ability of K/E-FR3C to form colonies in soft agar (Figure 1b) . With the aim to identify p100, we conducted in vitro substrate trapping experiments. Lysates prepared from K/E-FR3C expressing either WT-SHP2 or R/E-SHP2 were subjected to affinity precipitation with the GST fusion of the PTP domain of the SHP2 substrate-trapping mutant, termed DM-PTP (Agazie and Hayman, 2003a,) . As shown in Figure 1c , the DM-PTP precipitated p100 and two other phosphotyrosyl proteins, identified as p60 and p70, in R/E-SHP2 cells, but not in WT-SHP2 cells. As substrate trapping by the DM-PTP is Tyr(P) dependent, the indicated proteins could not be trapped from lysates of WT-SHP2 cells due to dephosphorylation. These results suggest that SHP2 modulates the Tyr phosphorylation of p100 that associates with K/E-FR3 (Agazie et al., 2003) , and p60 and p70 that do not associate with K/E-FR3 in these cells. The corresponding Coomassie blue-stained band of p100 was excised, eluted, digested with trypsin, and analysed by MS/MS mass spectroscopy that provides peptide masses and matching sequences; analysis of p60 and p70 is pending. Data base search using peptide sequences obtained from this analysis showed that two of the isolated peptides match hundred percent to amino acids 137-154 and 703-729 of a-catenin. Isolation of two matching peptides is the minimum requirement for positive identification of an unknown protein. Nonetheless, these results provided a critical clue as to the identity.
As the mass spectroscopy results were the minimum required, and in vitro pull down is far from what is happening within a cell, we corroborated these results by substrate trapping studies in intact cells, which approximates the in vivo situation. Thus, K/E-FR3C were infected with retroviruses expressing vector alone, WT-SHP2 or DM-SHP2 (the full-length substrate-trapping mutant of SHP2). A population of cells from each group resistant to blastocidin (the selection drug expressed by the retroviral vector) were grown to confluency and lyzed. These lysates were subjected to immunoprecipitation with anti-SHP2 antibody and immunoblotting with the indicated antibodies. As shown in Figure 1d (top panel), significant amount of a-catenin coprecipitated with DM-SHP2, but only basal with WT-SHP2 or vector control. Reprobing the membrane with antiTyr(P) antibody showed that a-catenin was highly Tyr phosphorylated (middle panel). In addition, p70 and p60, the unidentified potential SHP2 substrates, were Tyr phosphorylated suggesting that they can be trapped by the DM-SHP2 in intact cells. Further reprobing with anti-SHP2 antibody showed that there was no difference in the amount of WT-SHP2 and DM-SHP2 recovered during the immunoprecipitation reaction ( Figure 1d , bottom panel). These results confirmed that the phosphotyrosyl protein p100, which was trapped by the DM-PTP in vitro and DM-SHP2 in intact cells, is a-catenin.
Modulation of a-catenin Tyr phosphorylation by SHP2
The issue of a-catenin Tyr phosphorylation has been controversial (Kapus et al., 2000; Hu et al., 2001; Ozawa and Ohkubo, 2001) . The trapping of a-catenin by the DM-SHP2 in itself provides a clear indication that it becomes Tyr phosphorylated. As there was unequal amount of a-catenin protein due to the trapping effect, the results in Figure 1d (middle panel) could not be used to draw a definitive conclusion. Thus, we corroborated these findings by specifically immunoprecipitating acatenin and determining its Tyr phosphorylation status. Lysates prepared from confluent K/E-FR3C expressing vector alone, WT-SHP2 or R/E-SHP2 were immunoprecipitated and analysed by immunoblotting with anti-Tyr(P) antibody. a-Catenin in R/E-SHP2 cells was highly Tyr phosphorylated, but not in vector or WT-SHP2 cells (Figure 2a , top panel). Reprobing the membrane with anti-a-catenin antibody showed that the amount of a-catenin protein was comparable ( Figure 2a , bottom panel). When a-catenin was immunoprecipitated from nonconfluent cells that did not make intercellular contact, there was only basal level Tyr phosphorylation (data not shown). Therefore, a-catenin becomes Tyr phosphorylated in intercellular adhesion-dependent manner.
The enhanced a-catenin Tyr phosphorylation in R/E-SHP2 cells and its trapping by the DM-SHP2 suggest that a-catenin is an SHP2 substrate. To directly demonstrate this point, we conducted in vitro immunocomplex phosphatase assays. a-Catenin was immunoprecipitated from R/E-SHP2 cell lysates and subjected to PTPase assays as described in the Materials and methods. These samples were separated on a gel, and analysed by immunoblot with anti-Tyr(P) antibody. As shown in Figure 2b (top panel), a-catenin was highly Tyr phosphorylated in mock-treated sample (lane 1), which was abolished by treatment with WT-PTP for 10 min (lane 2), but not by the PTPase-dead R/E-SHP2 (lane 3). These results, together with the trapping studies, demonstrate that a-catenin is a target substrate of SHP2.
SHP2 downregulates a-catenin interaction with b-catenin
The above results show that a-catenin is a target substrate of SHP2. However, the biological significance of modulation of a-catenin Tyr phosphorylation by SHP2 was not clear. A well-characterized role of a-catenin is mediating the interaction between the actin cytoskeleton and adherens junction assembly via binding to both b-catenin and filamentous actin leading to enhanced actin polymerization and acto-myosin bundling. On the other hand, SHP2 is known to downregulate filamentous actin or actin stress fiber formation Inagaki et al., 2000; Kodama et al., 2000; Lacalle et al., 2002) . It was thus reasoned that one of the mechanisms by which SHP2 regulates actin cytoskeletal reorganization could be via modulation of Tyr phosphorylation of a-catenin, which might affect its interaction with bcatenin. Therefore, we determined the state of a-catenin and b-catenin interaction in K/E-FR3C expressing vector alone, WT-SHP2 or R/E-SHP2. Lysates prepared from the above cells were immunoprecipitated with antia-catenin and immunoblotted with anti-b-catenin antibody. As shown in Figure 3a (top panel), significant amount of b-catenin coprecipitated with a-catenin in cell expressing R/E-SHP2, but only basal in vector or WT-SHP2-expressing cells. Reprobing the membrane with anti-a-catenin antibody showed that the amount of a-catenin protein was comparable in all lanes ( Figure 3a , lower panel). These results suggest that SHP2 interferes with Tyr phosphorylation-dependent interaction of a-catenin with b-catenin.
The above results were further corroborated by reciprocal immunoprecipitation and immunoblotting experiments. Significantly higher amount of a-catenin coprecipitated with b-catenin in R/E-SHP2 cells, but only basal in vector or WT-SHP2 cells ( Figure 3b , top panel). However, reblotting with anti-b-catenin antibody showed that the amount of b-catenin protein recovered during immunoprecipitation reactions was not comparable; it was higher in R/E-SHP2 cells and lower in vector or WT-SHP2 cells (Figure 3b , lower panel). Given that b-catenin translocates to the nucleus in some cancers, we reasoned that this might be the case for its variation in transformed versus revertant cells. Thus, we analysed the level of both a-catenin and b-catenin in Triton-X-100 soluble fractions (without nuclear content, Figure 3c ) and whole-cell lysates (including nuclear content, Figure 3d ). There was no difference in the amount of a-catenin in both Inhibition of a-catenin by SHP2 promotes cell transformation J Burks and YM Agazie preparations. However, the amount of b-catenin was variable in Triton-X-100 soluble fractions, but comparable in whole-cell lysates suggesting that there was no difference in total b-catenin protein content, but in its intracellular compartmentalization. These results led us to further conduct anti-b-catenin immunoprecipitation experiments on whole-cell lysates. As expected, there was no difference in a-catenin that coprecipitated with b-catenin nor was there a difference in b-catenin recovered during the immunoprecipitation reaction ( Figure 3e ). Therefore, the amount of b-catenin available for interaction with a-catenin in vector or WT-SHP2 cells was low due to translocation to the nucleus. The absence of difference in immunoprecipitation experiments from whole-cell lysates, a protocol that allows compartmentalized proteins to mix, might be due to interaction outside the cell. Together, these results indicate that Tyr phosphorylation of a-catenin is highly correlated with its interaction with b-catenin and that this interaction is downregulated by SHP2.
In addition, they show that SHP2 increases nuclear bcatenin content.
SHP2 suppresses a-catenin translocation to the plasma membrane The findings that SHP2 downregulates the interaction of a-catenin with b-catenin raised the possibility that this might affect the translocation of a-catenin to the plasma membrane, to its site of action. We investigated this possibility by a confocal immunofluorescence microscopy. K/E-FR3C expressing vector, WT-SHP2 or R/E-SHP2 were seeded on cover slips, grown overnight and processed for immunofluorescence. These preparations were costained with anti-a-catenin to examine localization to the plasma membrane and with phalloidin to determine relationship to actin filaments. In conformation to the transformed phenotype shown in Figure 1a , the vector or WT-SHP2 expressing cells exhibited a polarized and spindle-shaped appearance, whereas the revertant R/E-SHP2 expressing cells showed a flattened and nonpolarized morphology ( Figure 4 ). There was stronger staining of a-catenin at cell-cell contact sites in R/E-SHP2 cells, but very little or none in vector or WT-SHP2 cells; a-catenin in vector or WT-SHP2 cells was defused through out the cytoplasm (Figure 4a) . A remarkable observation was that vector or WT-SHP2 cells could not form a-catenin-containing cell-cell contacts even when they grew in contact with each other and when there were more cells per field than the R/E-SHP2 cells. Phalloidin staining also showed remarkable differences in actin cytoskeletal reorganization between the transformed (vector or WT-SHP2) and revertant (R/E-SHP2) cells. Actin filaments in R/E-SHP2 cell were enormous, highly bundled, crosshatched, and traversed the cell from one end to the other. On the other hand, vector or WT-SHP2 cells had actin bundles only along the edges and polar ends, which may represent cortical actin described in other cell types (Figure 4a , phalloidin). The same experiment was performed on sparsely seeded cells, and pictures collected at higher magnification. In these preparations, it was possible to see lessbundled actin filaments in vector or WT-SHP2 cells running only parallel to the long axis without any crosshatching (see Figure 4b , phalloidin). In addition, let alone the vector and WT-SHP2 cells, even in R/E-SHP2 cells, the occurrence of a-catenin-stained structures was intercellular adhesion dependent. With regard to the relationship between actin and a-catenin, it was abundantly clear that most actin filaments in R/E-SHP2 cells ramified at a-catenin-stained structures, concurring with previous reports that a-catenin links actin filaments with adherens junction assembly (Aberle et al., 1994 (Aberle et al., , 1996 Hinck et al., 1994; Nathke et al., 1994) . As there were no a-catenin-stained intercellular contacts, the relationship between a-catenin and actin filaments was indiscernible in vector or WT-SHP2 cells. These results suggest that SHP2 downregulates a-catenin translocation to the plasma membrane, leading to inhibition of its interaction with the actin cytoskeleton. Thus, by Figure 4 SHP2 suppresses a-catenin translocation to the plasma membrane and its interaction with the actin cytoskeleton. K/E-FR3 expressing vector alone, WT-SHP2 or R/E-SHP2 were seeded on cover slips, incubated overnight and processed for confocal microscope analysis as described in the Materials and methods. These preparations were costained with anti-a-catenin and phalloidin. The white arrows show actin filaments not associated with a-catenin-stained structures (see merged pictures).
Inhibition of a-catenin by SHP2 promotes cell transformation J Burks and YM Agazie modulating a-catenin Tyr phosphorylation, SHP2 regulates actin cytoskeletal reorganization, which may translate into regulation of cell morphology and transformation.
Modulation of actin cytoskeletal reorganization by SHP2 through focal adhesions By and large, actin filaments in R/E-SHP2 cells were anchored to a-catenin-stained structures, but not in vector or WT-SHP2 cells. Thus, we reasoned that other factors might be involved in these cells. Even in R/E-SHP2 cells, it was possible to discern non-a-cateninbound actin filaments. Based on these results and previous reports (Turner, 2000) , we assumed that focal adhesions might also anchor actin filaments. Thus, we investigated the relationship between focal adhesions and actin filaments. To enhance cell attachment and to stimulate focal adhesion formation, cells were seeded on fibronectin-coated plates. After 4 h of incubation, they were processed for immunofluorescence confocal microscopy by staining with a specific antibody against paxillin, the known focal adhesion protein, and with rhodamin-labeled phalloidin. The vector or WT-SHP2 cells exhibited a highly polarized morphology reminiscent of migrating cells with focal adhesions forming primarily at the leading edge and scarcely at the rear end; no focal adhesions were observed on the sides of these cells. In contrast, R/E-SHP2 cells showed a nonpolarized and flattened morphology with more prominent and 'streaked' focal adhesions around the periphery (Figure 5) . Apparently, the distribution of focal adhesions appeared to dictate cell polarity. Not only was there a difference in distribution, but also in shape and size of focal adhesions. Focal adhesions at the leading edge of vector or WT-SHP2 cells were smaller and relatively rounded, whereas those at the rear end of these cells were streaked or elongated. On the other hand, most of focal adhesion in R/E-SHP2 cells was larger in size and elongated or streaked ( Figure 5 ). The streaked appearance might be related to a pulling and/or dragging force emanating from the contraction of actin cables (see Discussion). Most actin filaments in R/E-SHP2 cells were linked to
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Focal adhesion and actin filament interaction Figure 5 Modulation of actin cytoskeletal reorganization by SHP2 through focal adhesions. K/E-FR3C expressing vector, WT-SHP2 or R/E-SHP2 were seeded on fibronectin-coated coverslips for about 4 h and then processed for confocal microscopy. These preparations were costained with anti-paxillin antibody for focal adhesions and phalloidin for actin filaments. Pictures in (a) were taken at Â 20, whereas in (b) at Â 40. The merged pictures show the relationship between actin filaments and focal adhesions.
Inhibition of a-catenin by SHP2 promotes cell transformation J Burks and YM Agazie paxillin-stained focal adhesions at both ends providing a mechanistic explanation why they looked crosshatched. In vector or WT-SHP2, linkage of actin filaments to focal adhesions was apparent only at the front end. Thus, vector or WT-SHP2 cells could form stronger attachment at the leading edge allowing the cell to move in a defined direction, while R/E-SHP2 cells could not make significant migration due to the existence of strong attachment around the cells' periphery.
Regulation of adherens junction-mediated intercellular adhesion by SHP2
The findings that SHP2 suppresses a-catenin translocation to the plasma membrane via inhibition of its interaction with b-catenin (Figures 3 and 4) suggested that SHP2 might mediate oncogene-induced inhibition of adherens junction-mediated cell-cell contacts. In cells capable of forming such contacts, homophilic interaction between cadherin molecules expressed on adjacent cells forms the basic molecular zipper. NIH-3T3 cells (of fibroblast origin) express P-cadherin, and thus are capable of forming adherens junctions. By linking the cadherin-b-catenin complex with the actin cytoskeleton, a-Catenin strengthens adherens junction assembly, and consequently of intercellular contacts (Aberle et al., 1994 (Aberle et al., , 1996 Hinck et al., 1994; Nathke et al., 1994) . Thus, we investigated the effect of SHP2 on adherens junction-mediated intercellular adhesion in K/E-FR3C expressing vector, WT-SHP2 or R/E-SHP2. These cells were grown to confluency, and then processed for immunofluorescence confocal microscopy by costaining with anticadherin and anti-b-catenin antibodies. R/E-SHP2 cells exhibited intense cadherin or b-catenin staining at intercellular contact sites, but vector or WT-SHP2 cells did not ( Figure 6 ). In contrast, cadherin was diffusely distributed in the cytoplasm, and b-catenin was primarily localized in the nucleus in vector or WT-SHP2 cells. These results suggest that SHP2 inhibits adherens junction-mediated intercellular adhesion by disrupting a-catenin-b-catenin interaction, while at the same time enhancing b-catenin translocation to the nucleus where it may act as a transcription factor, confirming the results presented in Figure 3 .
Effect of SHP2 modulation of a-Catenin Tyr phosphorylation on cell transformation
Our previous report has shown that SHP2 effects K/E-FR3-induced transformation by positively modulating the Ras-ERK and PI3K-Akt signaling pathways (Agazie et al., 2003) . With regard to a-catenin, it was shown that Si-RNA-mediated ablation induces cellular hyperproliferation and enhances activation of the Ras-ERK signaling pathway (Vasioukhin et al., 2001 ). Thus, we reasoned that modulation of a-catenin Tyr phosphorylation by SHP2 might affect, not only cellcell adhesion, but also activation of the Ras-ERK
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Regulation of adherens junction and β-catenin localization Figure 6 Regulation of adherens junction-mediated intercellular adhesion by SHP2. The same cells were grown to confluency, and then processed for immunofluorescence confocal microscopy by costaining with anticadherin and anti-b-catenin antibodies. Note that R/E-SHP2 cells could form adherens junction-mediated intercellular adhesion, whereas vector or WT-SHP2 cells could not.
Inhibition of a-catenin by SHP2 promotes cell transformation J Burks and YM Agazie cascade by K/E-FR3. Analysis of the primary sequence of the b-catenin-binding region of a-catenin for potential Tyr phosphorylation sites indicated the existence of a single Tyr residue, Tyr148, toward the C-terminal end of this region. We mutated Tyr148 either to Asp, to create a gain-of-function mutant by mimic phosphorylation, or to Phe, to abolish phosphorylation and produce a loss-of function mutant. To differentiate from the endogenous a-catenin, we myc-tagged these constructs at their C-terminus and overexpressed them in K/E-FR3C by retrovirus-mediated infection. The wildtype form of a-catenin and vector alone were used as controls. First, we analysed the expression of these constructs by Western blot of lysates with anti-myc antibody. As shown in Figure 7a ( Inhibition of a-catenin by SHP2 promotes cell transformation J Burks and YM Agazie that Tyr148Asp-a-catenin has an enhanced interaction with b-catenin, while Tyr148Phe-a-catenin has only basal interaction when compared with the wild-type protein (Figure 7c , top panel). Reblotting with anti-myc antibody indicated that the amount of myc-tagged a-catenin recovered during immunoprecipitation was comparable (Figure 7c, bottom panel) . Analysis of the corresponding total cell lysates for ERK1/2 and Akt activation demonstrated that expression Tyr148Asp-acatenin has an inhibitory effect. The wild protein also showed modest inhibition of ERK1/2 and Akt activation (Figure 7d) . These cells were further tested for their ability to grow anchorage independently. As demonstrated in Figure 7e , expression of wild-type or Tyr148Asp-a-catenin suppresses colony formation in soft agar. Together, these results suggest that a-catenin plays a suppressor role in cell transformation and that SHP2, by dephosphorylating a-catenin, promotes mitogenic, cell survival and transformation signals.
Discussion
SHP2 is a ubiquitously expressed PTP with unique biological properties. As opposed to many PTPs, it positively modulates RTK signaling in vertebrates Feng and Pawson, 1994; Frearson and Alexander, 1998; Agazie and Hayman, 2003b) . The phosphotyrosine phosphatase SHP-2 participates in a multimeric signaling complex and regulates T-cell receptor (TCR) coupling to the Ras/mitogen-activated protein kinase (MAPK) pathway in Jurkat T cells, (Hadari et al., 1998) . Recently, we have demonstrated that SHP2 is essential for the transformation of NIH-3T3 cells by K/E-FR3 (Agazie et al., 2003) . In that study, we detected a phosphotyrosyl protein of B100 KDa (p100) that coprecipitates with K/E-FR3 in cells expressing dominant-negative SHP2 (R/E-SHP2). However, the identity of this protein as well as its relevance in SHP2-meditaed and K/E-FR3-induced cell transformation was not known. By a combination of substrate trapping, mass spectroscopy and immunoblot analyses, we have identified p100 as a-catenin, a vinculin-related protein involved in adherens junction assembly. We demonstrate that a-catenin is an SHP2 substrate that becomes Tyr phosphorylated in cell-cell adhesion-dependent manner. We further show that a-catenin Tyr phosphorylation is important for its interaction with the b-catenin, for enhancing adherens junction assembly and for its suppression of cell transformation. Phosphorylation of the conserved Tyr residue in the activation loop of Tyr kinases induces activating conformational changes (Hubbard and Till, 2000) . Also, K/E-FR3 that harbors Lys650-to-Glu mutation in its kinase domain is constitutively active may be due to a similar negative charge-induced activating conformational changes (Li et al., 1999; Tavormina et al., 1999; Bellus et al., 2000) . As a result, K/E-FR3 is transforming to fibroblasts, but its oncogenicity is totally dependent on the PTPase activity of SHP2 (Agazie et al., 2003) . As has been the case with several other oncogenic Tyr kinases, SHP2-mediated activation of the Ras-ERK and PI3K-Akt signaling pathways was essential for transformation (Agazie et al., 2003) . The detection of a highly Tyr phosphorylated protein, p100, in cells expressing R/E-SHP2 led us to assume that it might be a downstream effector of SHP2. The identification of p100 as a-catenin was unexpected simply because a-catenin is primarily involved in adherens junction assembly. Its well-documented role is to mediate the interaction of the b-catenin-cadherin complex with the actin cytoskeleton. However, a recent report (Vasioukhin et al., 2001) shows that Si-RNAmediated suppression of a-catenin expression induces cell hyperproliferation and enhances growth factorinduced Ras-ERK activation. Thus, the effect of modulation of a-catenin Tyr phosphorylation by SHP2 has a multifaceted dimension than just regulating cell-cell interaction.
The issue of a-catenin Tyr phosphorylation has been controversial (Kapus et al., 2000; Hu et al., 2001; Ozawa and Ohkubo, 2001) . The trapping of a-catenin by the DM-PTP in vitro (Figure 1c ) and DM-SHP2 in intact cells (Figure 2) suggests that it becomes Tyr phosphorylated. Furthermore, a-catenin immunoprecipitated from confluent K/E-FR3C expressing R/E-SHP2 was highly Tyr phosphorylated suggesting that it is a target substrate of SHP2. This was further confirmed by in vitro immunocomplex PTPase assays where we demonstrated that WT-PTP dephosphorylates a-catenin. Therefore, these results establish that a-catenin becomes Tyr phosphorylated and this event is modulated by SHP2.
It is well established that a-catenin mediates the interaction between the actin cytoskeleton and adherens junction assembly via binding to both b-catenin and filamentous actin or actin binding proteins such as vinculin and filamentous actin-nucleating formin proteins (Anastasiadis and Reynolds, 2000; Ireton et al., 2002; Kobielak and Fuchs, 2004) . This interaction stabilizes adherens junction-mediated intercellular adhesion and enhances Rho-mediated actin filament formation or sometimes called stress fiber formation. On the other hand, SHP2 is known to downregulate Rho activation and consequently of stress fiber formation, but its role in adherens junction has not been shown. Our findings show that SHP2 negatively regulates the interaction of a-catenin with b-catenin implying an inhibitory role on adherens junction-mediated intercellular adhesion. Although we did not investigate the effect of SHP2 on b-catenin Tyr phosphorylation, its enhanced translocation to the nucleus in the background of WT-SHP2 suggests that b-catenin is not affected. Previous work also shows that b-catenin Tyr phosphorylation disrupts its interaction with cadherins, facilitating its translocation to the nucleus where it acts as a transcription factor (Barth et al., 1997; Abutaily et al., 2003) . With regard to a-catenin, however, Tyr phosphorylation exerts an opposite effect; it increases interaction with b-catenin. These findings are supported by a similar observation in p120 catenin (p120 CTN ) where its Tyr phosphorylation enhances its ability to interact with the cytoplasmic region of cadherins leading to aggregation of homophilic cadherin complexes expressed on adjacent cells and consequently of strengthening intercellular adhesion (Anastasiadis and Reynolds, 2000; Ireton et al., 2002) . Thus, our findings are the first to show that Tyr phosphorylation of a-catenin positively modulates its interaction with b-catenin.
The enhanced interaction of a-catenin with b-catenin in R/E-SHP2 cells raised the possibility that SHP2 might modulate the localization of a-catenin to plasma membrane. Our results demonstrated that R/E-SHP2 cells could form a-catenin-stained structures at the plasma membrane in intercellular adhesion-dependent manner, while vector or WT-SHP2 cells could not even when they grew in contact with each other and when there were more cells per field than the R/E-SHP2 cells. Therefore, SHP2 interferes with the localization of a-catenin to the plasma membrane, to its site of action. Given that a-catenin Tyr phosphorylation (Figure 2 ) as well as its interaction with b-catenin (Figure 3 ) was significantly enhanced in R/E-SHP2 cells, and that its localization to the plasma membrane was inhibited in vector or WT-SHP2 cells, but enhanced in R/E-SHP2 cells (Figure 4) , it is clear that SHP2 negatively regulates the function of a-catenin. This conclusion is supported by the remarkable cytoskeletal differences between the R/E-SHP2 and the vector or WT-SHP2 cells. The localization of a-catenin to adherens junction sites creates binding sites for filamentous actin. In R/E-SHP2 cells, actin filaments were enormous, highly bundled, crosshatched, and bound to a-catenin-stained structures, while in vector or WT-SHP2 cells they were fewer, less bundled, and run only parallel to the long axis of the cell with no relationship to a-catenin. Thus, by interfering with a-catenin translocation to the plasma membrane, SHP2 inhibits the interaction between the actin cytoskeleton and adherens junction assembly.
Absence of a-catenin-stained structures in vector or WT-SHP2 cells indicates that other structures must anchor actin filaments in these cells. The presence of actin filaments that did not ramify at a-catenin-stained structures in R/E-SHP2 cells also suggests the existence of an additional factor. We found that focal adhesions were the sole anchorage providers for actin filaments in vector or WT-SHP2 cells, but they cooperate with adherens junction in R/E-SHP2 cells. The observation that SHP2 suppresses a-catenin translocation to the plasma membrane was a clear indication that SHP2 modulates adherens junction-mediated intercellular adhesion. In cells capable of forming such contacts, homophilic interaction between cadherin molecules expressed on adjacent cells forms the basic molecular zipper (Aberle et al., 1994 (Aberle et al., , 1996 Hinck et al., 1994; Nathke et al., 1994) . NIH-3T3 cells primarily express P-cadherin, and thus are capable of forming adherens junctions. Immunofluorescence studies demonstrated that vector or WT-SHP2 cells were unable to form cadherin and/or b-catenin-stained adherens junction even when they grew in contact with or on top of each other. On the other hand, R/E-SHP2 cells were able to form strong cadherin-and b-catenin-stained adherens junction. These results confirm that SHP2 mediates oncogene-induced inhibition of adherens junctionmediated intercellular adhesion.
The increased b-catenin nuclear staining in vector or WT-SHP2 cells suggests that SHP2 promotes localization of b-catenin to the nucleus via inhibition of its interaction with a-catenin. b-catenin plays distinctive roles depending on its localization within a cell. At the plasma membrane, b-catenin enhances adherens junction-mediated intercellular adhesion by directly interacting with the cytoplasmic region of the cadherins and the N-terminal region of a-catenin. a-catenin in turn binds to the actin cytoskeleton, leading to stabilization of cadherin-mediated intercellular adhesion. On the other hand, cellular events that disrupt adherens junction assembly lead to Tyr phosphorylation-dependent translocation of b-catenin to the nucleus where it acts as a transcription factor in cooperation with the lymphoid enhancer factor (LEF) family of transcription factors (Merdek et al., 2004) leading to the expression of oncogenes such as c-myc and cyclin D1 (Barth et al., 1997; Abutaily et al., 2003) . Dramatic differences in cell morphology, actin cytoskeletal reorganization, and adherens junction-mediated intercellular adhesion were observed between the transformants and revertants. Our results show that modulation of a-catenin Tyr phosphorylation by SHP2 has a multifaceted impact: (1) inhibits a-catenin translocation to the plasma membrane and consequently of its interaction with b-catenin, (2) enhances cell migration by inhibiting intercellular adhesion and modulating the distribution of focal adhesions, (3) suppresses the binding of actin filaments to the plasma membrane leading to changes in the dynamics of actin polymerization and (4) enhances the translocation of b-catenin to the nucleus where it might act as a transcription factor.
How does dephosphorylation of a-catenin by SHP2 positively impact cell transformation? To directly answer this question, we mutated the only potential phosphorylation site, Tyr148, in the b-catenin-binding region of a-catenin. This undertaking was partly based on a previous report that showed that the N-terminal region of b-catenin that mediates interaction with a-catenin exhibits a positively charged surface. It was thus reasonable to assume that Tyr phosphorylation of a-catenin (acquisition of a negative charge) enhances its interaction with b-catenin due to charge attraction. This assumption was confirmed by trapping studies where DM-PTP could not pull down Ty148Asp or Tyr148Phe mutants, suggesting that this site is a target substrate of SHP2. As expected, mutation of Tyr148 to Asp enhanced, while to Phe abolished the interaction of a-catenin with b-catenin. Furthermore, overexpression of Tyr148Asp or wild-type a-catenin suppressed ERK1/2 and Akt activation and colony formation in soft agar to a variable degree, while Tyr148Phe did not show any effect (Figure 7) . In support of our observation, it was previously demonstrated that interference with a-catenin function enhances growth factor-induced activation of the Ras-ERK pathway and iduces hyperproliferation of skin epithelium (Vasioukhin et al., 2001) . In addition, loss of a-catenin function was shown contributes to cell transformation (Morton et al., 1993; Bullions et al., 1997) . Our previous work in the EGFR system has shown that SHP2 promotes the Ras-ERK signaling pathway by interfering with RasGAP, the downregulator of Ras (Agazie and Hayman, 2003b) . Thus, our findings in the current report add a new dimension to the mechanism of SHP2 in promoting the Ras-ERK pathway. In other words, SHP2 mediates RTK-induced activation of the Ras-ERK and, by implication, the PI3K-Akt pathways, not only by blocking RasGAP, but also by interfering with the suppressive role of a-catenin. Given that the Ras-ERK and PI3K-Akt pathways are essential for K/E-FR3-induced cell transformation (Agazie et al., 2003) and that dephosphorylation of a-catenin by SHP2 enhances the activation of these signaling pathways, then, inhibition of a-catenin by SHP2 promotes cell transformation. In addition, suppression of adherens junction and modulation of focal adhesion formation and actin cytoskeletal reorganization could contribute to cell transformation. Although the effect of SHP2 on adherens junction and acti cytoskeleton could be ascribed to inhibition of Tyr phosphorylation-dependent interaction of a-catenin with b-catenin, it is not clear how this event enhances the Ras-ERK and PI3K-Akt pathways. It will be interesting to address these unresolved issues in future studies.
Materials and methods
Cells, cell culture, antibodies and reagents NIH-3T3 cells transformed with constitutively active fibroblast growth factor receptor 3, hereinafter referred to as K/E-FR3C (Agazie et al., 2003) were used for this study. They were grown in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal calf serum at 371C with 7% CO 2 . Anti-paxillin antibody was purchased from Upstate Biotechnologies, Lake Placid, NY, USA, anti-a-catenin, anti-b-catenin and anticadherin antibodies were from Santa Cruz, Santa Cruz, CA, USA, anti-PTP1D (SHP2) from Pharmagen, San Diego, CA, USA, and antiphosphotyrosine monoclonal antibody from Cell Signaling, Danvers, MA, USA. Horseradish peroxidaseconjugated secondary antibodies were purchased from Amersham, Piscataway, NJ, USA, rhodamine-labeled phalloidin and fibronectin from Sigma, St. Louis, MO, USA, and FITCor rhodamine-labeled secondary antibodies from Molecular Probes (Invitrogen, Carlsbad, CA, USA).
Colony formation in soft agar
Soft agar colony formation studies were conducted as described previously (Agazie et al., 2002) . Briefly, 6 cm cell culture plates were overlaid with 0.3% agar in the growing medium and allowed to solidify. Approximately 10 4 cells suspended in 3 ml of growth medium were mixed with melted agar to a final concentration of 0.3% and immediately poured onto the agar overlay. After 5 min of incubation at room temperature, cells were transferred to a 371C and 7% CO 2 incubator for 6 days. During this time, cells were fed with soft agar medium once at the 72 h time point. Colony size and number was determined after 6 days and pictures taken under Olympus IX71 microscope equipped with a digital camera.
Production of cells stably expressing SHP2 proteins
Transformation of NIH-3T3 with K/E-FR3, subcloning of wild-type or mutant SHP2 cDNA into a retroviral vector expressing blastocidin resistance gene, and the production of stable cell lines was reported recently (Agazie et al., 2003) . Briefly, K/E-FR3C, were infected with retroviruses expressing vector alone, wild-type SHP2 (WT-SHP2), dominant-negative SHP2 (R465E-SHP2, hereinafter named R/E-SHP2) or trapping-mutant SHP2 (C459S/D425A-SHP2, hereinafter named DM-SHP2). Infection was performed by adding virus-containing medium to cells and incubation for approximately 6 h. After 36 h in a growth medium, cells were treated with blastocidin (5 mg/ml in the growth medium) to remove uninfected cells. A population of blastocidin-resistant cells was used in all the experiments reported here.
Preparation of lysates, immunoprecipitation and immunoblotting
Cells were lyzed in lysis buffer containing 10 mM Tris-HCl, pH7.4, 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 10% glycerol, 1% Triton-X-100, 5 mM Na orthovanadate and protease inhibitor cocktail. Except for the preparation of whole-cell lysates that include sonication, all other lysates were prepared solely by lysis with triton. After clearing by centrifugation, lysates were incubated with anti-SHP2 or anti-a-catenin antibody overnight at 41C with an additional incubation for 2-h after addition of protein-A sepharose beads. The precipitates were washed three times with cell lysis buffer, eluted by boiling with Laemmli sample buffer, and separated on 8% denaturing polyacrylamide gel. After transfer onto a nitrocellulose membrane and blocking with 3% bovine serum albumin, membranes were stained with the primary antibody either overnight at 41C or for 2 h at room temperature. The secondary antibody staining was for 1 h at room temperature. The chemiluminescence detection method was used for all Western blot experiments.
Isolation and identification of SHP2 substrates P100 was isolated by affinity precipitation with the glutathione S-transferase (GST) fusion of the PTP domain of the DM-SHP2, termed DM-PTP. We have reported the construction, expression and purification of the GST fusion PTP domains previously (Agazie and Hayman, 2003b) . For affinity precipitation, DM-PTP was first captured on glutathione Sepharose beads (B20 ml packed volume per mg of GST-PTP per sample) by incubation for 30 min at 41C. Precipitates were washed three times with bacterial lysis buffer (25 mM Tris-HCl pH7.4, 150 mM NaCl, 10% glycerol, 1% NP-40), and twice with eukaryotic cell lysis buffer (see above). The source materials for substrate isolation were K/E-FR3C expressing WT-SHP2 or R/E-SHP2. Lysates prepared as above were cleared by centrifugation, added to DM-PTP captured on beads and incubated for 4 h at 41C. Precipitates were washed five times with cell lysis buffer, and eluted by boiling for 10 min with Laemmli sample buffer. Samples were separated on a denaturing 10% polyacrylamide gel in replica -one-tenth for immunoblot analysis and the nine-tenth for Coomassie blue staining. The one-tenth samples were transferred onto a nitrocellulose membrane and analysed by immunoblot with anti-Tyr(P), while the Coomassie blue-stained samples for mass spectroscopic analysis.
Immunocomplex phosphatase assay
For this assay, a-catenin was immunoprecipitated from K/E-FR3C expressing R/E-SHP2. This was because, R/E-SHP2 expression preserves a-catenin Tyr phosphorylation. After washing three times with lysis buffer, precipitates were further washed two times with PTPase buffer (Tris-HCl pH7.0, 50 mM NaCl and 10 mM dithiothreitol) and resuspended in 100 ml PTPase buffer. GST fusion of the PTP domain of WT-SHP2, hereinafter termed WT-PTP, was used as an enzyme. A similar construct of the R/E-SHP2 was used as a negative control. The fusions were purified on glutathione sepharose beads as recommended by the company (Pharmacia, Kalamazoo, MI, USA), and quantified by measuring absorbance at 280 nm and comparison with BSA standards. The immunocomplex PTPase reaction was performed by adding 100 ng of WT-PTP or R/E-PTP and incubation for 10 min at 371C. a-Catenin was then eluted by boiling with Laemmli sample buffer, separated on an 8% gel and analysed by Western blot.
Immunofluorescence microscopy K/E-FR3C expressing vector alone, WT-SHP2 or R/E-SHP2 were seeded on cover slips coated or not coated with fibronectin (10 mg/ml in PBS) and incubated for desired time points. They were then fixed with 4% paraformaldehyde for 20 min, washed three times with PBS (5 min long in each case), permeablized with 0.2% Triton-X-100 in PBS for 30 min, and blocked with 3% bovine serum albumin in PBS for 1 h. Next, samples were stained with a primary antibody at 41C overnight (B12 h), washed three times with PBS containing 0.2% Triton-X-100, and incubated with fluorescent-labeled secondary antibody or phalloidin for 1 h at room temperature. Finally, samples were washed three times, mounted on a microscopic slide and scanned with laser scanning microscope 510 (Zeiss).
Site-directed mutagenesis
Mutation of Tyr residues in the N-terminal region of a-catenin was performed using the Stratagene protocol. The sense and antisense strands for Tyr-to-Asp mutation were 5 0 -CCG GTTGCTGATTTTGGCTGACATGGCAGATGTCGACA AATTACTTGTTCAG-CTGAAAGTTGTGGAAGATGG-3 0 and 5 0 -CCATCTTCCACAACTTTCAGCTGAA-CAAGTA ATTTGTCGACATCTGCCATGTCAGCCAAAATCAGCA ACCGG-3 0 , respectively. And, the sense and antisense primers for Tyr148-to-Phe mutation were 5 0 -CCGGTTGCTGATT TTGGCTGACATGGCAGATGTCTTCAAATTACTTGTT CAG-CTGAAAGTTGTGGAAGATGG-3 0 and 5 0 -CCATC TTCCACAACTTTCAGCTGAA-CAAGTAATTTGAAGA CATCTGCCATGTCAGCCAAAATCAGCAACCGG-3 0 .
